Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS). - Quinquenel A; Leprêtre S; Dilhuydy MS; Bussot L; Marjanovic Z; Benbrahim O; Guièze R; Santagostino A; Dartigeas C; Feugier P; Roos-Weil D; Damaj G; et al. (Annals of hematology, 2025)